Prognosis and outcome determinants after heart failure diagnosis in patients who underwent aortic valvular intervention.
Aortic stenosis; Aortic valvular intervention; Heart failure; Mortality; Determinants
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
26
03
2021
received:
24
11
2020
accepted:
19
05
2021
pubmed:
1
6
2021
medline:
29
10
2021
entrez:
31
5
2021
Statut:
ppublish
Résumé
To study clinical phenotype, prognosis for all-cause and cardiovascular (CV) mortality and predictive factors in patients with incident heart failure (HF) after aortic valvular intervention (AVI) for aortic stenosis (AS). In this retrospective, observational study we included patients from the Swedish Heart Failure Registry (SwedeHF) recorded 2003-2016, with AS diagnosis and AVI before HF diagnosis. The AS diagnosis was established according to International Classification of Diseases 10th revision (ICD-10) codes, thus without information concerning clinical or echocardiographical data on the aortic valve disease. The patients were divided into two subgroups: left ventricular ejection fraction (LVEF) ≥ 50% (AS-HFpEF) and <50% (AS-HFrEF). We individually matched three controls with HF from the SwedeHF without AS (control group) for each patient. Baseline characteristics, co-morbidities, survival status and outcomes were obtained by linking the SwedeHF with two other Swedish registries. We used Kaplan-Meier curves to present time to all-cause mortality, cumulative incidence function for time to CV mortality and Cox proportional hazards model to evaluate the relative difference between AS-HFrEF and AS-HFpEF and AS-HF and controls. The crude all-cause mortality was 49.0%, CV mortality 27.9% in AS-HF patients, respectively 44.7% and 26.6% in matched controls. The adjusted risk for all-cause mortality and CV mortality was similar in HF, regardless of LVEF vs. controls. No significant difference in factors predicting higher all-cause mortality was observed in AS-HFrEF vs. AS-HFpEF, except for diabetes (only in AS-HFrEF), with statistically significant interaction predicting death between the two groups. In this nationwide SwedeHF study, we characterized incident HF population after AVI. We found no significant differences in all-cause and CV mortality compared with general HF population. They had virtually the same predictors for mortality, regardless of LVEF.
Identifiants
pubmed: 34057321
doi: 10.1002/ehf2.13451
pmc: PMC8318512
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3237-3247Informations de copyright
© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
J Card Surg. 2019 Dec;34(12):1577-1590
pubmed: 31600005
Scand Cardiovasc J. 2020 Apr;54(2):115-123
pubmed: 31674218
J Am Coll Cardiol. 2019 Jul 9;74(1):26-33
pubmed: 31272548
BMJ. 2016 Sep 28;354:i5065
pubmed: 27683072
J Thorac Cardiovasc Surg. 2019 Jun;157(6):2189-2197.e14
pubmed: 30501946
J Am Coll Cardiol. 2004 Feb 4;43(3):317-27
pubmed: 15013109
Heart. 2006 Feb;92(2):208-12
pubmed: 15908482
Eur Heart J. 2008 Feb;29(3):339-47
pubmed: 18156618
N Engl J Med. 2006 Jul 20;355(3):260-9
pubmed: 16855266
Eur J Cardiothorac Surg. 2014 Sep;46(3):386-97; discussion 397
pubmed: 24554075
Eur Heart J. 2012 Jul;33(14):1750-7
pubmed: 21821849
Circulation. 2003 Feb 25;107(7):984-91
pubmed: 12600911
Circulation. 1992 Jul;86(1):38-46
pubmed: 1535573
J Am Coll Cardiol. 2012 Nov 6;60(19):1854-63
pubmed: 23062541
Circulation. 1981 Jul;64(1):126-34
pubmed: 7237709
Heart. 2017 Nov;103(21):1696-1703
pubmed: 28432156
N Engl J Med. 2014 Aug 21;371(8):744-56
pubmed: 25140960
Eur J Anaesthesiol. 2013 Nov;30(11):695-703
pubmed: 24047727
Eur Heart J. 2003 May;24(9):863-70
pubmed: 12727154
Eur J Epidemiol. 2017 Sep;32(9):765-773
pubmed: 28983736
Am J Cardiol. 1999 Sep 1;84(5):611-2, A9
pubmed: 10482169
Circulation. 2002 Mar 26;105(12):1503-8
pubmed: 11914262
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Eur J Heart Fail. 2016 Jan;18(1):54-65
pubmed: 26634799
Card Fail Rev. 2019 May 24;5(2):99-105
pubmed: 31179020
Eur Heart J. 2016 Sep 07;37(34):2658-67
pubmed: 26559386
Diabetes Obes Metab. 2019 Jun;21(6):1277-1290
pubmed: 30724013
BMC Public Health. 2020 Jan 10;20(1):36
pubmed: 31924185
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
Ups J Med Sci. 2019 Jan;124(1):65-69
pubmed: 30092697
ESC Heart Fail. 2021 Aug;8(4):3237-3247
pubmed: 34057321
Eur J Heart Fail. 2010 Jan;12(1):25-31
pubmed: 20023041
Circulation. 2018 Sep 4;138(10):971-985
pubmed: 30354532
Heart. 2013 Mar;99(6):396-400
pubmed: 22942293
Lancet. 2006 Sep 16;368(9540):1005-11
pubmed: 16980116
Eur Heart J. 2016 Nov 7;37(42):3232-3245
pubmed: 27523477
JACC Heart Fail. 2015 Jul;3(7):542-550
pubmed: 26160370